Conditions: Diabetes Mellitus, Type 2 Healthy Volunteers
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 58
Healthy volunteers: yes

Brief summary:
This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks.

Doses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.

Detailed description:

Arms:
arm 1: 0.5 milligrams (mg) dulaglutide administered once subcutaneously (SQ) to healthy participants in 1 of 3 treatment periods arm 2: 0.75 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods arm 3: 1.5 mg dulaglutide administered once SQ to healthy participants in 1 of 3 treatment periods arm 4: Placebo administered once SQ to healthy participants in 1 of 3 treatment periods arm 5: 0.5 mg dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM) once weekly SQ for 4 weeks arm 6: 0.75 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks arm 7: 1.5 mg dulaglutide administered to participants with T2DM once weekly SQ for 4 weeks arm 8: Placebo administered to participants with T2DM once weekly SQ for 4 weeks

Interventions: intervention 1: Dulaglutide intervention 2: Placebo
Intervention descriptions: intervention 1: None intervention 2: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.

Protocol document: